• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧盟医疗软件初创企业的商业模式框架:混合方法研究

A Business Model Framework for Software as a Medical Device Startups in the European Union: Mixed Methods Study.

作者信息

Martjan Rahel Sophie, Weimar Sascha Noel, Terzidis Orestis

机构信息

Institute for Entrepreneurship, Technology Management and Innovation (EnTechnon), Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany.

出版信息

J Med Internet Res. 2025 May 23;27:e67328. doi: 10.2196/67328.

DOI:10.2196/67328
PMID:40408133
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12144475/
Abstract

BACKGROUND

With the introduction of Regulation (EU) 2017/745, also known as the Medical Device Regulation (MDR), startups aiming to develop software as a medical device (SaMD) in the European Union are confronted with stringent and complex regulations, and many of them struggle with them. Complying with the MDR is a costly, time-consuming endeavor requiring expertise and substantial financial resources. However, it opens the door for new revenue models, such as reimbursement pathways. Consequently, the MDR significantly shapes the business model of startups. Early on, the regulation needs to be considered for business modeling to survive the conformity assessment process financially. Business model frameworks are tools that reduce complexity by focusing on the key aspects of a business model. Thereby, the risk of overlooking essential elements can be minimized. A framework directly integrating the MDR could alleviate the intricate circumstances in which SaMD startups are entangled.

OBJECTIVE

This study focused on deriving a business model framework for startups aiming to develop SaMD under the MDR. With the framework, we strived to facilitate business modeling for SaMD startups.

METHODS

The study is based on a 3-step approach. First, a systematic literature review was carried out, resulting in a concept matrix and an overview of business model frameworks developed and applied in the digital health sector. Subsequently, 13 interviews were conducted with experts and startups in the SaMD industry. On the basis of the literature analysis and expert interviews, along with the MDR requirements for SaMD, we developed the SaMD business model framework.

RESULTS

The SaMD business model framework consists of 13 interrelated components, with the MDR being a pivotal component. The centerpiece of the framework is the "regulatory value arc," which is the trio of intended purpose, value propositions, and customer segments. For each component, valuable input is provided, making the framework tailored to startups aiming to develop SaMD.

CONCLUSIONS

The findings highlight the crucial role of regulations in business modeling. Notably, the MDR is a central regulation for startups aiming to develop SaMD. The study uncovers the impact of the MDR on business modeling for SaMD startups. Our research provides a framework that integrates this regulation, thereby reducing its complexity and facilitating startups in deriving a sustainable business model. Concurrently, this research integrates the domains of business modeling and the MDR. Therefore, it contributes to the academic discourse in both fields and addresses a notable gap in the existing literature.

摘要

背景

随着欧盟第2017/745号法规(即《医疗器械法规》,简称MDR)的出台,旨在在欧盟开发作为医疗器械的软件(SaMD)的初创企业面临着严格而复杂的法规,许多企业在应对这些法规时遇到困难。遵守MDR是一项成本高昂、耗时的工作,需要专业知识和大量资金。然而,它为新的收入模式(如报销途径)打开了大门。因此,MDR显著塑造了初创企业的商业模式。在早期,为了在财务上挺过合格评定过程,在进行商业模式构建时就需要考虑该法规。商业模式框架是通过关注商业模式的关键方面来降低复杂性的工具。由此,可以将忽略关键要素的风险降至最低。一个直接整合MDR的框架可以缓解SaMD初创企业所陷入的复杂局面。

目的

本研究聚焦于为旨在依据MDR开发SaMD的初创企业推导一个商业模式框架。借助该框架,我们努力为SaMD初创企业的商业模式构建提供便利。

方法

本研究基于一种三步法。首先,进行了系统的文献综述,得出了一个概念矩阵以及数字健康领域已开发和应用的商业模式框架概述。随后,对SaMD行业的专家和初创企业进行了13次访谈。基于文献分析、专家访谈以及MDR对SaMD的要求,我们开发了SaMD商业模式框架。

结果

SaMD商业模式框架由13个相互关联的组件组成,其中MDR是关键组件。该框架的核心是“监管价值弧”,即预期目的、价值主张和客户细分这三者。针对每个组件都提供了有价值的输入,使得该框架是为旨在开发SaMD的初创企业量身定制的。

结论

研究结果凸显了法规在商业模式构建中的关键作用。值得注意的是,MDR是旨在开发SaMD的初创企业的核心法规。该研究揭示了MDR对SaMD初创企业商业模式构建的影响。我们的研究提供了一个整合该法规的框架,从而降低其复杂性,并帮助初创企业推导可持续的商业模式。同时,本研究整合了商业模式构建和MDR这两个领域。因此,它为这两个领域的学术讨论做出了贡献,并弥补了现有文献中一个显著的空白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/8db1f5ea2e5b/jmir_v27i1e67328_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/d01d5d1b871a/jmir_v27i1e67328_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/388626917fd9/jmir_v27i1e67328_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/8e5c1df1a7c5/jmir_v27i1e67328_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/8db1f5ea2e5b/jmir_v27i1e67328_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/d01d5d1b871a/jmir_v27i1e67328_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/388626917fd9/jmir_v27i1e67328_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/8e5c1df1a7c5/jmir_v27i1e67328_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23d6/12144475/8db1f5ea2e5b/jmir_v27i1e67328_fig4.jpg

相似文献

1
A Business Model Framework for Software as a Medical Device Startups in the European Union: Mixed Methods Study.欧盟医疗软件初创企业的商业模式框架:混合方法研究
J Med Internet Res. 2025 May 23;27:e67328. doi: 10.2196/67328.
2
Business Venturing in Regulated Markets-Taxonomy and Archetypes of Digital Health Business Models in the European Union: Mixed Methods Descriptive and Exploratory Study.受监管市场中的商业冒险——欧盟数字健康商业模式的分类与原型:混合方法描述性与探索性研究
J Med Internet Res. 2025 Jan 9;27:e65725. doi: 10.2196/65725.
3
Innovation Process and Industrial System of US Food and Drug Administration-Approved Software as a Medical Device: Review and Content Analysis.美国食品和药物管理局批准的软件作为医疗器械的创新过程和工业体系:综述与内容分析。
J Med Internet Res. 2023 Nov 24;25:e47505. doi: 10.2196/47505.
4
Navigating regulatory challenges across the life cycle of a SaMD.应对软件即医疗器械(SaMD)生命周期中的监管挑战。
J Biomed Inform. 2025 Jul;167:104856. doi: 10.1016/j.jbi.2025.104856. Epub 2025 May 21.
5
The use of predetermined change control plans to enable the release of new versions of software as a medical device.使用预先确定的变更控制计划以实现作为医疗设备的软件新版本的发布。
Expert Rev Med Devices. 2025 Mar;22(3):261-275. doi: 10.1080/17434440.2025.2468787. Epub 2025 Feb 28.
6
Clinical Simulation in the Regulation of Software as a Medical Device: An eDelphi Study.作为医疗器械的软件监管中的临床模拟:一项电子德尔菲研究。
JMIR Form Res. 2024 Jun 25;8:e56241. doi: 10.2196/56241.
7
[In search of a travel guide-results from a survey of E‑health startup companies].[寻找旅行指南——电子健康初创公司调查结果]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Mar;61(3):291-297. doi: 10.1007/s00103-018-2692-4.
8
Health-tech startups in healthcare service delivery: A scoping review.医疗保健服务提供中的健康科技初创企业:范围综述。
Soc Sci Med. 2021 Jun;278:113949. doi: 10.1016/j.socscimed.2021.113949. Epub 2021 Apr 19.
9
Artificial Intelligence-Based Software as a Medical Device (AI-SaMD): A Systematic Review.基于人工智能的软件作为医疗器械(AI-SaMD):一项系统综述。
Healthcare (Basel). 2025 Apr 3;13(7):817. doi: 10.3390/healthcare13070817.
10
Improving startups through excellence initiatives: addressing circular economy and innovation.通过卓越计划改善初创企业:应对循环经济与创新。
Environ Dev Sustain. 2023 Apr 21:1-47. doi: 10.1007/s10668-023-03247-4.

本文引用的文献

1
Business Venturing in Regulated Markets-Taxonomy and Archetypes of Digital Health Business Models in the European Union: Mixed Methods Descriptive and Exploratory Study.受监管市场中的商业冒险——欧盟数字健康商业模式的分类与原型:混合方法描述性与探索性研究
J Med Internet Res. 2025 Jan 9;27:e65725. doi: 10.2196/65725.
2
Exploring Impediments Imposed by the Medical Device Regulation EU 2017/745 on Software as a Medical Device.探索欧盟2017/745号医疗器械法规对作为医疗器械的软件所施加的障碍。
JMIR Med Inform. 2024 Sep 5;12:e58080. doi: 10.2196/58080.
3
Innovation Process and Industrial System of US Food and Drug Administration-Approved Software as a Medical Device: Review and Content Analysis.
美国食品和药物管理局批准的软件作为医疗器械的创新过程和工业体系:综述与内容分析。
J Med Internet Res. 2023 Nov 24;25:e47505. doi: 10.2196/47505.
4
Impact of the new European medical device regulation: a two-year comparison.新欧洲医疗器械法规的影响:两年比较。
Biomed Tech (Berl). 2023 Nov 13;69(3):317-326. doi: 10.1515/bmt-2023-0325. Print 2024 Jun 25.
5
The new European Medical Device Regulation: Friend or foe for hospitals and patients?新的《欧盟医疗器械法规》:对医院和患者是敌是友?
Injury. 2023 Oct;54 Suppl 5:110907. doi: 10.1016/j.injury.2023.110907. Epub 2023 Jun 20.
6
The Challenges for Manufacturers of the Increased Clinical Evaluation in the European Medical Device Regulations: A Quantitative Study.《医疗器械法规中增加临床评估对制造商的挑战:一项定量研究》
Ther Innov Regul Sci. 2023 Jul;57(4):783-796. doi: 10.1007/s43441-023-00527-z. Epub 2023 May 17.
7
The dominant logic of Big Tech in healthcare and pharma.大科技在医疗保健和制药领域的主导逻辑。
Drug Discov Today. 2023 Feb;28(2):103457. doi: 10.1016/j.drudis.2022.103457. Epub 2022 Nov 24.
8
The 4P telehealth business framework for Iran.伊朗的 4P 远程医疗业务框架。
BMC Med Inform Decis Mak. 2022 Oct 9;22(1):266. doi: 10.1186/s12911-022-02011-4.
9
Navigating Medical Device Certification: A Qualitative Exploration of Barriers and Enablers Amongst Innovators, Notified Bodies and Other Stakeholders.医疗器械认证的探索:创新者、公告机构和其他利益相关者之间的障碍和促进因素的定性研究。
Ther Innov Regul Sci. 2023 Mar;57(2):238-250. doi: 10.1007/s43441-022-00463-4. Epub 2022 Oct 4.
10
Development, evaluation and implementation of a digital behavioural health treatment for chronic pain: study protocol of the multiphase DAHLIA project.慢性疼痛数字行为健康治疗的开发、评估与实施:多阶段DAHLIA项目研究方案
BMJ Open. 2022 Apr 15;12(4):e059152. doi: 10.1136/bmjopen-2021-059152.